{"schema_version":"secwatch.filing_event.v1","accession":"0001701541-25-000038","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.186005+00:00","generated_at":"2026-05-16T23:47:35.626830+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Black Diamond Q3 net loss $8.5M, cash $135.5M; silevertinib Phase 2 ORR data due Q4 2025","bullets":["Cash, cash equivalents and investments $135.5M as of Sept 30, 2025; funds operations into Q4 2027.","Net loss $8.5M in Q3 2025 vs $15.6M in Q3 2024; R&D expenses fell to $7.4M from $12.9M.","ORR and preliminary duration of treatment data from silevertinib Phase 2 in 1L non-classical EGFRm NSCLC expected later this quarter.","PFS data from Phase 2 trial expected in H1 2026; company plans FDA feedback on registrational path.","Exploring partnership opportunities for silevertinib in NSCLC and glioblastoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001701541-25-000038","json":"https://secwatch.observer/filing/0001701541-25-000038.json","markdown":"https://secwatch.observer/filing/0001701541-25-000038.md","text":"https://secwatch.observer/filing/0001701541-25-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000170154125000038/0001701541-25-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000170154125000038/bdtx-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:47:35.626830+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}